Associations among plasma markers for N-methyl-d-aspartate receptor hypofunction, redox dysregulation, and insufficient myelination in patients with schizophrenia
- PMID: 38694089
- PMCID: PMC11061757
- DOI: 10.1016/j.heliyon.2024.e30193
Associations among plasma markers for N-methyl-d-aspartate receptor hypofunction, redox dysregulation, and insufficient myelination in patients with schizophrenia
Abstract
Background: Several hypotheses regarding the pathomechanisms of schizophrenia have been proposed. If schizophrenia is a unitary disease, then these pathological processes must be linked; however, if such links do not exist, schizophrenia may best be considered a group of disorders. Only a few studies have examined the relationships among these pathomechanisms. Herein, we examined the relationships among deficient myelination, NMDA receptor hypofunction, and metabolic dysregulation by measuring various plasma markers and examining their correlations.
Methods: Plasma samples were collected from 90 patients with schizophrenia and 68 healthy controls. Concentrations of nardilysin (N-arginine dibasic convertase, NRDC), a positive regulator of myelination, the NMDA receptor co-agonist d-serine and glycine, various additional amino acids related to NMDA receptor transmission (glutamate, glutamine, and l-serine), and homocysteine (Hcy), were measured. Concentrations were compared using independent samples t-test or logistic regression, and associations were evaluated using Pearson's correlation coefficients.
Results: Plasma glycine (t = 2.05, p = 0.042), l-serine (t = 2.25, p = 0.027), and homocysteine (t = 3.71, p < 0.001) concentrations were significantly higher in patients with schizophrenia compared to those in healthy controls. Logistic regression models using age, sex, smoking status, glutamine, glutamate, glycine, l-serine, d-serine, homocysteine, and NRDC as independent variables revealed significantly lower plasma d-serine (p = 0.024) and NRDC (p = 0.028), but significantly higher l-serine (p = 0.024) and homocysteine (p = 0.001) in patients with schizophrenia. Several unique correlations were found between NMDA receptor-related amino acids and NRDC in patients with schizophrenia compared to those in healthy controls, while no correlations were found between plasma homocysteine and other markers. No associations were found between plasma marker concentrations and disease status or cognitive function in patients with schizophrenia, except for a significant correlation between plasma glycine and full intelligence quotient.
Conclusion: Reduced myelination and NMDA receptor hypofunction may be related to pathological mechanisms in schizophrenia, while homocysteine dysregulation appears to be an independent pathological process. These results suggest that schizophrenia may be a group of disorders with unique or partially overlapping etiologies.
Keywords: Homocysteine; Nardilysin; Schizophrenia; d-serine; l-serine.
© 2024 The Authors. Published by Elsevier Ltd.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment.Neurosci Lett. 2014 Oct 17;582:93-8. doi: 10.1016/j.neulet.2014.08.052. Epub 2014 Sep 10. Neurosci Lett. 2014. PMID: 25218715
-
Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.Arch Gen Psychiatry. 2003 Jun;60(6):572-6. doi: 10.1001/archpsyc.60.6.572. Arch Gen Psychiatry. 2003. PMID: 12796220
-
Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP).Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1905-12. doi: 10.1016/j.pnpbp.2008.07.022. Epub 2008 Sep 16. Prog Neuropsychopharmacol Biol Psychiatry. 2008. PMID: 18835577 Clinical Trial.
-
Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.Pharmacol Ther. 2008 Dec;120(3):317-32. doi: 10.1016/j.pharmthera.2008.08.004. Epub 2008 Aug 27. Pharmacol Ther. 2008. PMID: 18805436 Review.
-
Potential role of amino acids in pathogenesis of schizophrenia.Int J Health Sci (Qassim). 2017 Jul-Sep;11(3):63-68. Int J Health Sci (Qassim). 2017. PMID: 28936154 Free PMC article. Review.
References
-
- American Psychiatric Association . fifth ed. Text Revision. , Amer Psychiatric Pub Inc; Arlington, VA: 2022. Diagnostic and Statistical Manual of Mental Disorders.
-
- Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatr. 1991;148:1301–1308. - PubMed
LinkOut - more resources
Full Text Sources